Mode
Text Size
Log in / Sign up

Early-oral antibiotics showed safety superiority and efficacy equivalence versus IV-only in patients requiring prolonged therapy

Early-oral antibiotics showed safety superiority and efficacy equivalence versus IV-only in patients…
Photo by Raimond Klavins / Unsplash
Key Takeaway
Consider early-oral antibiotics for prolonged therapy as they showed safety superiority and efficacy equivalence versus IV-only.

This randomized controlled trial enrolled patients who required two or more weeks of IV antibiotics for all but central nervous system infections. The study took place across five hospitals in a rural health system. Participants were assigned to an early-oral group or a control group receiving IV-only therapy.

The early-oral group showed a significantly lower adverse event rate of 3.2% versus 6.5% in the control group. The P value for this difference was .02. The cumulative hazard for the first study-related adverse event was also lower in the early-oral group with a hazard ratio of 0.24. The 95% confidence interval for this hazard ratio ranged from .08 to .75, with a P value of .01.

Therapeutic efficacy was reported as equivalent between the groups. No specific p-values or confidence intervals were reported for efficacy outcomes. A significant positive association was found between the COPAT:OPAT program consult ratio and cumulative enrollment, with an R2 value of 0.54 and a P value less than .001.

Safety data indicated significantly lower adverse event rates in the early-oral group. Information regarding serious adverse events, discontinuations, and tolerability was not reported. The study did not report funding sources or conflicts of interest. Implementation of the COPAT Trial accelerated practice transformation in the setting.

Study Details

Study typeRct
Sample sizen = 2
EvidenceLevel 2
Follow-up3.0 mo
PublishedApr 2026
View Original Abstract ↓
BACKGROUND: Extensive literature has established equivalent efficacy of early intravenous (IV) to oral antibiotic transition. However, there is variability in adoption across practice settings. Unlike Outpatient Parenteral Antimicrobial Therapy (OPAT) programs, Complex Outpatient Antimicrobial Therapy with Oral Agents (COpAT) programs face significant implementation science challenges. We used a clinical trial with broad enrollment criteria to determine the impact of early oral transition in a real-world setting and studied its influence on practice transformation. METHODS: Comparing Oral versus Parenteral Antimicrobial Therapy (COPAT) Trial was a pragmatic, randomized controlled trial at 5 hospitals in 1 rural health system. Patients who required 2 or more weeks of IV antibiotics (for all but central nervous system infections) were randomized 2:1 to experimental (early-oral) group or control (IV-only) group. Two primary outcomes and hypotheses were assessed at 3 months: early-oral group safety superiority and efficacy equivalence. Clinical cases of patients who completed the trial were presented at multiple forums. RESULTS: The trial was stopped early after two-thirds enrollment for a significant safety benefit. Early-oral group demonstrated a significantly lower adverse event rate (3.2% versus 6.5%, P = .02). Lower cumulative hazard for first study-related adverse event in early-oral group (hazard ratio, 0.24; 95% confidence interval, .08-.75; P = .01) appeared to emerge by day 10. Therapeutic efficacy was equivalent. Cumulative enrollment in the trial had a significant association with the COpAT:OPAT program consult ratio (R2= 0.54, P < .001). CONCLUSIONS: Early oral antibiotic transition was significantly safer. At our academic health system, implementation of the COPAT Trial accelerated practice transformation. CLINICAL TRIALS REGISTRATION: NCT05977868.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.